
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma has demonstrated a strong financial position, ending the quarter with cash, cash equivalents, and marketable securities totaling $320 million, reflecting a $23 million increase quarter-over-quarter attributed to a private placement. The company has solidified the profile of its key product candidate, rondecabtagene autoleucel (ronde-cel), as a leader in durability for CD19/CD20 CAR T-cell therapies, which positions it favorably against competitors. Additionally, expert feedback on Lyell’s existing LYL273 dataset suggests that the company's product candidates are achieving clinical success in challenging markets, validating its potential for growth and enhancing the overall outlook for the stock.
Bears say
Lyell Immunopharma has reported a decrease in research and development expenses, which fell to $28.2 million in the third quarter of 2025 from $34.9 million in the second quarter, suggesting potential budget constraints. There are several significant risks associated with the company's pipeline, including challenges in capturing market share in the CAR-T market, potential efficacy deterioration, unforeseen safety events, and long-term dilution risks that could impact investor confidence. Furthermore, the lack of definitive evidence regarding the durability of the treatment outcomes and the management of associated toxicities raises concerns about the company's ability to establish its therapies as standard-of-care options in a competitive and lucrative market.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares